Preclinical in vitro investigation to evaluate novel molecular targeted therapy options for neuroendocrine neoplasms by Aristizabal Prada, Elke Tatjana
P a g e  | 1 
 
Aus der medizinische Klinik und Poliklinik IV der  
Ludwig-Maximilians-Universität München  
Direktor: Prof. Dr. med. Martin Reincke  
  




Preclinical in vitro investigation to evaluate 







  zum Erwerb des Doktorgrades der Humanbiologie 
 an der Medizinischen Fakultät der  








vorgelegt von   
Elke Tatjana Aristizabal Prada  
aus  München 
 2018 
P a g e  | 2 
 
Mit Genehmigung der Medizinischen Fakultät  der 










Berichterstatter:  Prof. Dr. med. Christoph J. Auernhammer 
   
Mitberichterstatter:  
Priv.- Doz. Dr. med. Klaus Metzeler 
Prof. Dr. med. Thomas Knösel 
   
Mitbetreuung durch den 




Prof. Dr. Reinhard Hickel  
  























P a g e  | 3 
 
Eidesstattliche Versicherung  
  
  
Aristizabal Prada, Elke Tatjana  
 
Name, Vorname  
   
  
Ich erkläre hiermit an Eides statt,   
    
dass ich die vorliegende Dissertation mit dem Thema   
  
  





selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle 
Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich 
gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe.   
  
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher 







 München, den 12.08.18                                             Elke Tatjana Aristizabal Prada      
 













Eidesstattliche Versicherung    Stand: 31.01.2013  







3.1. General introduction into neuroendocrine tumors…………………………………...5 
3.2. The novel cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) alone and in 
dual-targeting approaches demonstrates antitumoral efficacy in neuroendocrine 
tumors in vitro………………………………………………………………………………...6 
3.3. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in 




6. Publication 1……………………………………………………………………………...13 

















P a g e  | 5 
 
1.   ABBREVIATIONS 
 
Chk   Checkpoint kinase 
CDK   Cyclin-dependent kinase 
p21   Cyclin-dependent kinase inhibitor 1 
p16   Cyclin dependent kinase inhibitor 2A 
Caspase  Cysteinyl-aspartate specific protease 
DNA   Deoxyribonucleic acid 
MDM2  E3 ubiquitin ligase mouse double minute 2 homolog (MDM2) 
EGFR   Epithelial growth factor receptor 
4EBP1  Eukaryotic translation initiation factor 4E-binding protein 1 
RAD001  Everolimus, mTORC1 inhibitor (Novartis, Basel) 
ERK   Extracellular signal-regulated kinase 1 
FACS   Flow cytometric analysis 
5-FU   5-fluorouracil 
γ-irradiation  Gamma-irradiation 
G1 phase  Gap 1 phase 
G2 phase  Gap 2 phase 
GEP-NET  Gastroenteropancreatic neuroendocrine tumor 
GTP   Guanosine triphosphate 
MTH1   Human Mut-T homologue 1 
IC50                    Inhibitory concentration of 50 % 
IGFR   Insulin-like growth factor receptor 
mTOR  Mechanistic / mammalian target of rapamycin 
mTORC1  Mammalian target of rapamycin complex 1 
µM   Micro molar 
MEK   Mitogen-activated protein kinase kinase 
TH588  MTH1 inhibitor (Thomas Helleday, Karolinska Institutet, Sweden) 
nM   Nano molar 
NET   Neuroendocrine tumor 
%   Percent 
PI3K   Phosphoinositid-3-kinase 
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PARP   Poly (ADP-ribose)-Polymerase 
PCNA   Proliferating-Cell-Nuclear-Antigen 
Akt   Protein kinase B  
Raf   Rapidly accelerated fibrosarcoma protein 
Ras   Rat sarcoma protein 
ROS   Reactive oxygen species 
Rb   Retino-blastoma protein 
LEE011  Ribociclib, CDK4/6 inhibitor (Novartis, Basel) 
p70S6K  Ribosomal protein S6 kinase beta-1 
S phase  Synthesis phase 
E2F   Transcription factor E2F1 
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3.   INTRODUCTION 
 
3. 1.  General introduction into neuroendocrine tumors  
 
Neuroendocrine tumors (NETs) of the gastroenteropancreatic (GEP) system are highly 
complex and heterogeneous tumors, regarding their physiologic and genetic make-up 
and originate from distinct cell precursors [1]. GEP-NETs are frequently metastasized 
at the time of diagnosis, due to an absence of symptoms and curative resection is often 
impossible [2-4]. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are 
after colorectal cancer the second most common gastrointestinal malignancy [4] with 
increasing incidence [5, 6].  Despite an increasing knowledge of the tumor biology, 
genetics, epigenetics and novel biomarkers, the overall outcome and survival of GEP-
NETs has gained very little over the last decades [4, 7, 8]. Furthermore, systemic 
therapeutic approaches for GEP-NETs, such as biotherapy, chemotherapy, molecular 
targeted therapy and peptide receptor radionuclide therapy are limited in their 
efficiency [9-11]. The paucity of successful therapeutic agents in GEP-NET is mostly 
due to the complexity, the rarity, the intrinsic differences in malignant potential because 
of their heterogeneity and the dissimilar clinical presentation [1, 4]. Molecularly 
targeted therapies with the multi-tyrosine kinase inhibitor sunitinib or the mTORC1 
inhibitor everolimus are approved for treatment of pancreatic NETs [12-14]. Everolimus 
has recently also been approved for treatment of lung and gastrointestinal NETs [15]. 
The promising molecular targeting agent everolimus downregulates the mTOR / 
p70S6K pathway, one of the most important and oncogenic signaling cascades in 
GEP-NETs [16-18]. The PI3K-Akt-mTOR axis is frequently over-activated in cancers, 
including GEP-NETs, causing cellular survival, proliferation and protein synthesis [11, 
19]. Unfortunately only a subset of patients respond to everolimus treatment, due to 
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intrinsic resistance or the development of a de novo resistance in response to long 
term treatment [20-24]. Compensatory feed-back activation of PI3K-Akt signaling in 
response to mTORC1 inhibition, as well as cross-talk activation of other signaling 
pathways such as the Ras-Raf-MEK-ERK cascade in response to molecular targeting 
help to escape cancer cell death and are well described in NET cells [19, 25-27]. 
Hence, novel therapeutic strategies, including molecularly targeted therapeutics, are 
urgently needed [9, 14]. Dual-targeting approaches might provide a rationale to 
overcome acquired or intrinsic resistance, prevent feed-backs within and between 
signaling pathways and enhance single substance treatment [24, 28, 29]. 
 
The aim of this thesis was to evaluate different novel molecular targeted therapy 
options for neuroendocrine neoplasms based on an in vitro model: 
 
 
3.2. The novel cyclin-dependent kinase 4/6 inhibitor 
ribociclib (LEE011) alone and in dual-targeting 
approaches demonstrates antitumoral efficacy in 
neuroendocrine tumors in vitro 
Cyclin dependent kinases (CDKs) are the key regulators of the cell cycle and aberrant 
expression of these CDKs, due to gene mutation, amplification or overexpression often 
lead to the formation of cancer [30]. A very promising molecular targeting approach for 
GEP-NETs is the selective CDK4/6 inhibitor LEE011 (Novartis, Basel) by 
downregulating the proliferative CyclinD-CDK4/6-Rb axis (Fig. 1) [29]. Currently a 
clinical phase 2 trial with LEE011 is recruiting patients with advanced NETs of foregut 
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origin (NCT02420691) and another clinical phase 2 trial is recruiting patients with 
CDK4/6 pathway activated tumors (NCT02187783), substantiating the probable 
clinical relevance of targeting the CyclinD-CDK4/6-Rb axis. 
 
   
Fig. 1. Proposed and simplified mode of action of the CDK4/6 inhibitor LEE011 on the cell cycle. a 
Activated CyclinD-CDK4/6-Rb axis leads to G1/S cell cycle progression via the phosphorylation of Rb 
and subsequent activation of the transcription factor E2F. b Blocking the CyclinD-CDK4/6-Rb axis leads 
to G1 phase cell cycle arrest through either the endogenous CDK4/6 inhibitor p16 or the small molecule 
CDK4/6 inhibitor LEE011 
 
Using human neuroendocrine pancreatic BON1, pancreatic islet QGP1, 
bronchopulmonary NCI-H727 and ileal GOT1 cell lines we demonstrated the 
antitumoral efficacy of the novel cyclin-dependent kinase 4/6 inhibitor ribociclib 
(LEE011) alone and in dual-targeting approaches in vitro [29]. In this study we applied 
cellular survival assays, Western blot analysis, flow cytometric analysis (FACS) and 
Caspase-3/7 activity assays. The cell viability decreased in a time- and dose-
dependent manner in BON1, QGP1 and NCI-H727 cells upon LEE011 treatment, while 
GOT1 cells were treatment resistant. High expression levels of endogenous Rb and 
Cyclin D1 were associated with treatment sensitivity towards CDK4/6 inhibition in 
NETs. LEE011 caused dephosphorylation of Rb and a subsequent G1 phase cell cycle 
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arrest. The combinational treatment of LEE011 with 5-fluorouracil (5-FU) or everolimus 
showed a significant enhancement in inhibition of cell viability when compared to the 
respective single substance treatments, due to PI3K-Akt-mTOR and Ras-Raf-MEK-
ERK pathway downregulation and cooperative cell cycle component downregulation. 
Conversely, LEE011 also demonstrated antagonizing effects in combination with 5-
FU, by seemingly protecting NET cells from the DNA damaging effects of the 
chemotherapeutic agent through blocking PARP cleavage and caspase 3/7 activity. 
Taken together our results, CDK4/6 inhibition with LEE011 might be an efficient new 
therapeutic rationale for NETs either alone or in dual-targeting approaches, especially 
in combination with everolimus. We recommend clinical studies to ratify the efficacy of 
LEE011 and everolimus as dual-targeted therapy in neuroendocrine tumors. 
 
3.3. The MTH1 inhibitor TH588 demonstrates anti-tumoral 
effects alone and in combination with everolimus, 5-FU 
and gamma-irradiation in neuroendocrine tumor cells 
 
Cancer cells often display a dysfunctional redox regulation with a high level of reactive 
oxygen species damaging the DNA and the free nucleotide pool [31, 32]. The 
nucleotide pool-sanitizing enzyme MTH1 (human Mut-T homologue 1) was shown to 
be of pivotal importance for the progression and the survival of cancer cells, preventing 
the incorporation of damaged nucleotides into the DNA (Fig. 2) [33, 34].  Recently, 
several new small-molecule inhibitors targeting the nucleotide-sanitizing enzyme 
MTH1 (TH287, TH588 and S-crizotinib) were described to specifically induce lethality 
in a broad spectrum of cancer cells without harming untransformed tissues [35, 36]. 
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However the validity of MTH1 as a promising target against cancer has been 
questioned recently and the striking anti-proliferative effects of MTH1 inhibitors such 




Fig. 2. Proposed mode of action of TH588. MTH1 prevents the incorporation of damaged nucleotides 
into the DNA and hence protects cancer cells from the lethal effects caused by reactive oxygen species 
(ROS). By inhibiting MTH1 cancer cell death is restored. 
 
With this study we contributed to the assessment of cellular mechanisms and 
molecular signaling pathways implicated in the cellular response to TH588 treatment 
[40]. Using a panel of heterogeneous NET cell lines (BON1, QGP1, H727 and GOT1), 
we tested TH588 alone or in combination with the mTOR inhibitor everolimus, 5-FU 
and -irradiation. Here we applied cellular survival assays, Western blot analysis, 
Caspase-3/7 activity assays, FACS analysis, oxidative stress level assays and colony 
formation assays to determine the clonogenic cell survival after -irradiation. TH588 
MTH1 prevents DNA incorporation of G*and thus foments cancer cell survival, due to a 
gene pool sanitizing function.       
      TH588 blocks MTH1 and restores cancer cell death. 
ROS 
dGTP 
DNA incorporation of G* 
        DNA damage 





8-oxo-dGTP 8-oxo-dG = G* 
8-oxo-dGMP 
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caused cancer cell death by downregulating the PI3K-Akt-mTOR axis and inducing 
apoptosis, rather than causing augmentation of the cellular oxidative stress level. 
These effects were even enhanced when TH588 was combined with everolimus or 5-
FU, due to an even stronger downregulation of the PI3K-Akt-mTOR axis and 
augmentation of apoptosis but not oxidative stress. Furthermore TH588 demonstrated 
a radiosensitizing potential in combination with -irradiation (radiotherapy), one of most 
important treatment modalities in nowadays cancer treatment [41]. Our data thus not 
only provided new insights into how TH588 kills cancer cells but also depicted novel 
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4. ABSTRACT 
GEP-NETs are highly complex, rare and heterogeneous tumor entities [1]. Current 
treatment approaches are unsatisfying, due to their limited efficacy [2-4]. Ergo, novel 
therapeutic strategies, including molecularly targeted therapeutics, are urgently 
needed [9, 14]. The aim of this doctoral thesis was to evaluate different novel 
molecular targeted therapy options for neuroendocrine neoplasms in vitro. By 
targeting different signaling pathways, we obtained novel insights into NET tumor 
biology and assessed possible novel treatment strategies. Several dual-targeting 
approaches prevented feed-back loops within a signaling pathway, as well as cross-
talk activation between signaling pathways and enhanced single substance 
treatment. This cumulative doctoral thesis is based on the following original 
publications: 
 
 The novel cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) alone and 
in dual -targeting approaches demonstrates antitumoral efficacy in 
neuroendocrine tumors in vitro; Neuroendocrinology. 2017 Feb; doi: 
10.1159/000463386. PMID: 28226315. Aristizabal Prada ET, Nölting S, 
Spöttl G, Maurer J, Auernhammer CJ. 
 
 
 The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in 
combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine 
tumor cells. PLoS ONE. 2017 May; doi: 10.1371/journal.pone.0178375. PMID: 
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5. ZUSAMMENFASSUNG 
GEP-NETs sind hoch komplexe, seltene und heterogene Tumor-Entitäten [1]. 
Derzeitige Behandlungsmöglichkeiten sind aufgrund ihrer begrenzten Effektivität 
nicht zufriedenstellend [2-4]. Daher werden neue Behandlungsstrategien, wie 
molekular zielgerichtete Therapien, dringend benötigt [9, 14]. Das Ziel dieser 
Doktorarbeit war es, verschiedene neue molekular zielgerichtete Therapieansätze für 
neuroendokrine Neoplasien in vitro zu evaluieren. Durch das „targeting“ von 
verschiedenen Signalwegen konnten neue Einblicke in die Tumor-Biologie von NETs 
erzielt und neue mögliche Behandlungsstrategien erstellt werden. Einige „duale-
targeting“ Ansätze konnten „feed-back“ Mechanismen innerhalb eines Signalwegs 
oder die Aktivierung zwischen unterschiedlichen Signalwegen verhindern und 
verbesserten zudem die Einzelsubstanzbehandlung. Die kumulative Dissertation 
basiert auf den folgenden Originalveröffentlichungen: 
 
 The novel cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) alone and 
in dual -targeting approaches demonstrates antitumoral efficacy in 
neuroendocrine tumors in vitro; Neuroendocrinology. 2017 Feb; doi: 
10.1159/000463386. PMID: 28226315. Aristizabal Prada ET, Nölting S, 
Spöttl G, Maurer J, Auernhammer CJ. 
 
 
 The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in 
combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine 
tumor cells. PLoS ONE. 2017 May; doi: 10.1371/journal.pone.0178375. PMID: 
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